MD Anderson has tapped an innovative new company to improve the efficacy of cancer treatments. Photo via mdanderson.org

The sad reality is that not every cancer responds to medication, but a new collaboration is taking steps to close the gaps for scores of patients who were previously left without a clear solution.

The University of Texas MD Anderson Cancer Center and Nexo Therapeutics announced last week that they are collaborating, a move that could lead to the discovery of therapies that could work for patients with limited treatment options.

The Colorado- and Massachusetts-based company joins forces with Houston’s cancer-fighting powerhouse after emerging from stealth with a $60 million series A.

“For many cancer patients, there are no therapies that target the fundamental drivers of their disease,” says Nexo’s founder and CEO, Andrew Phillips, in a press release. He goes on to say that the company’s innovations in covalent chemistry and chemical biology, along with cancer biology and medical chemistry allows it to advance novel therapies.

But in order to get the drugs that Nexo creates onto the market, it is taking advantage of MD Anderson’s first-rate translational research and expertise in drug development. Specifically, Nexo will work with MD Anderson’s TRACTION (Translational Research to AdvanCe Therapeutics and Innovation in ONcology) platform. The pairing will allow the two bodies to accelerate the development of small-molecule therapies through drug-enabling studies.

“Together with Nexo’s innovative platform, our integrated approach to translational research and drug development is poised to design and rapidly advance novel therapies against high priority oncology targets,” says Tim Heffernan vice president of Oncology Research for TRACTION at MD Anderson, in a press release. “This collaboration highlights our commitment to advancing innovative new medicines that address critical unmet needs for our patients.”

TRACTION is part of MD Anderson’s Therapeutics Discovery Division. It combines a team of doctors, researchers, and drug development specialists to bring therapies from discovery to clinical trials. TRACTION researchers will work with Nexo to identify cancers that might be susceptible to their treatments, then find strategies to target them, and finally use biomarkers to help optimize patient selection.

Nexo will help to provide funding to support this research and will retain rights to programs under the collaboration, and will take sole responsibility for development, manufacturing, and commercialization. Meanwhile, MD Anderson may receive royalties and future payments based on milestones as they are obtained. But the real reward will be treating patients who were previously low on options.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston investment firm names tech exec as new partner

new hire

Houston tech executive Robert Kester has joined Houston-based Veriten, an energy-focused research, investment and strategy firm, as technology and innovation partner.

Kester most recently served as chief technology officer for emissions solutions at Honeywell Process Solutions, where he worked for five years. Honeywell International acquired Houston-based oil and gas technology company Rebellion Photonics, where Kester was co-founder and CEO, in 2019.

Honeywell Process Solutions shares offices in Houston with the global headquarters of Honeywell Performance Materials and Technologies. Honeywell, a Fortune 100 conglomerate, employs more than 850 people in Houston.

“We are thrilled to welcome Robert to the Veriten team,” founder and CEO Maynard Holt said in a statement, “and are confident that his technical expertise and skills will make a big contribution to Veriten’s partner and investor community. He will [oversee] every aspect of what we do, with the use case for AI in energy high on the 2025 priority list.”

Kester earned a doctoral degree in bioengineering from Rice University, a master’s degree in optical sciences from the University of Arizona and a bachelor’s degree in laser optical engineering technology from the Oregon Institute of Technology. He holds 25 patents and has more than 25 patents pending.

Veriten celebrated its third anniversary on January 10, the day that the hiring of Kester was announced. The startup launched with seven employees.

“With the addition of Dr. Kester, we are a 26-person team and are as enthusiastic as ever about improving the energy dialogue and researching the future paths for energy,” Holt added.

Kester spoke on the Houston Innovators Podcast in 2021. Listen here

.

SpaceX loses mega rocket in latest thrilling Starship test flight

Testing

SpaceX launched its Starship rocket on its latest test flight Thursday, but the spacecraft was destroyed following a thrilling booster catch back at the pad.

Elon Musk’s company said Starship broke apart — what it called a “rapid unscheduled disassembly." The spacecraft's six engines appeared to shut down one by one during ascent, with contact lost just 8 1/2 minutes into the flight.

The spacecraft — a new and upgraded model making its debut — was supposed to soar across the Gulf of Mexico from Texas on a near loop around the world similar to previous test flights. SpaceX had packed it with 10 dummy satellites for practice at releasing them.

A minute before the loss, SpaceX used the launch tower's giant mechanical arms to catch the returning booster, a feat achieved only once before. The descending booster hovered over the launch pad before being gripped by the pair of arms dubbed chopsticks.

The thrill of the catch quickly turned into disappointment for not only the company, but the crowds gathered along the southern tip of Texas.

“It was great to see a booster come down, but we are obviously bummed out about [the] ship,” said SpaceX spokesman Dan Huot. “It’s a flight test. It’s an experimental vehicle," he stressed.

The last data received from the spacecraft indicated an altitude of 90 miles and a velocity of 13,245 mph.

Musk said a preliminary analysis suggests leaking fuel may have built up pressure in a cavity above the engine firewall. Fire suppression will be added to the area, with increased venting and double-checking for leaks, he said via X.

The 400-foot rocket had thundered away in late afternoon from Boca Chica Beach near the Mexican border. The late hour ensured a daylight entry halfway around the world in the Indian Ocean. But the shiny retro-looking spacecraft never got nearly that far.

SpaceX had made improvements to the spacecraft for the latest demo and added a fleet of satellite mockups. The test satellites were the same size as SpaceX’s Starlink internet satellites and, like the spacecraft, were meant to be destroyed upon entry.

Musk plans to launch actual Starlinks on Starships before moving on to other satellites and, eventually, crews.

It was the seventh test flight for the world’s biggest and most powerful rocket. NASA has reserved a pair of Starships to land astronauts on the moon later this decade. Musk’s goal is Mars.

Hours earlier in Florida, another billionaire’s rocket company — Jeff Bezos’ Blue Origin — launched the newest supersized rocket, New Glenn. The rocket reached orbit on its first flight, successfully placing an experimental satellite thousands of miles above Earth. But the first-stage booster was destroyed, missing its targeted landing on a floating platform in the Atlantic.